Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials?

Various clinical outcome measures are commonly applied in clinical trials on specific immunotherapy for allergic rhinoconjunctivitis with or without asthma to provide evidence of its clinical efficacy. These "primary endpoints" measure clinical symptoms as well as the use for concomitant m...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Pfaar, Oliver (VerfasserIn) , Kleine-Tebbe, Jörg (VerfasserIn) , Hörmann, Karl (VerfasserIn) , Klimek, Ludger (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 28 April 2011
In: Immunology and allergy clinics of North America
Year: 2011, Jahrgang: 31, Heft: 2, Pages: 289-309
ISSN:1557-8607
DOI:10.1016/j.iac.2011.02.004
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.iac.2011.02.004
Volltext
Verfasserangaben:O. Pfaar, J. Kleine-Tebbe, K. Hörmann, L. Klimek

MARC

LEADER 00000caa a2200000 c 4500
001 1824360223
003 DE-627
005 20230710100623.0
007 cr uuu---uuuuu
008 221202s2011 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.iac.2011.02.004  |2 doi 
035 |a (DE-627)1824360223 
035 |a (DE-599)KXP1824360223 
035 |a (OCoLC)1389742612 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Pfaar, Oliver  |d 1972-  |e VerfasserIn  |0 (DE-588)12385900X  |0 (DE-627)706454049  |0 (DE-576)293913099  |4 aut 
245 1 0 |a Allergen-specific immunotherapy  |b which outcome measures are useful in monitoring clinical trials?  |c O. Pfaar, J. Kleine-Tebbe, K. Hörmann, L. Klimek 
264 1 |c 28 April 2011 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.12.2022 
520 |a Various clinical outcome measures are commonly applied in clinical trials on specific immunotherapy for allergic rhinoconjunctivitis with or without asthma to provide evidence of its clinical efficacy. These "primary endpoints" measure clinical symptoms as well as the use for concomitant medication. "Secondary outcome endpoints" are represented by health-related quality of life (HRQoL), "well-days," provocation-tests, in vitro tests and others. This article reviews different methods assessing the clinical outcome of trials on both subcutaneous and sublingual immunotherapy, and highlights potential advantages and drawbacks of each method. 
650 4 |a Allergens 
650 4 |a Biomarkers 
650 4 |a Clinical Trials as Topic 
650 4 |a Desensitization, Immunologic 
650 4 |a Epitopes 
650 4 |a Humans 
650 4 |a Immunoglobulin G 
650 4 |a Nasal Mucosa 
650 4 |a Outcome Assessment, Health Care 
700 1 |a Kleine-Tebbe, Jörg  |d 1957-2023  |e VerfasserIn  |0 (DE-588)120308150  |0 (DE-627)696553805  |0 (DE-576)292151640  |4 aut 
700 1 |a Hörmann, Karl  |d 1948-  |e VerfasserIn  |0 (DE-588)130123749  |0 (DE-627)49171193X  |0 (DE-576)266607438  |4 aut 
700 1 |a Klimek, Ludger  |d 1964-  |e VerfasserIn  |0 (DE-588)172705037  |0 (DE-627)697637476  |0 (DE-576)133562751  |4 aut 
773 0 8 |i Enthalten in  |t Immunology and allergy clinics of North America  |d Amsterdam [u.a.] : Elsevier, 1996  |g 31(2011), 2, Seite 289-309  |h Online-Ressource  |w (DE-627)507904974  |w (DE-600)2222334-4  |w (DE-576)9507904972  |x 1557-8607  |7 nnas  |a Allergen-specific immunotherapy which outcome measures are useful in monitoring clinical trials? 
773 1 8 |g volume:31  |g year:2011  |g number:2  |g pages:289-309  |g extent:11  |a Allergen-specific immunotherapy which outcome measures are useful in monitoring clinical trials? 
856 4 0 |u https://doi.org/10.1016/j.iac.2011.02.004  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20221202 
993 |a Article 
994 |a 2011 
998 |g 172705037  |a Klimek, Ludger  |m 172705037:Klimek, Ludger  |d 60000  |d 62100  |e 60000PK172705037  |e 62100PK172705037  |k 0/60000/  |k 1/60000/62100/  |p 4  |y j 
998 |g 130123749  |a Hörmann, Karl  |m 130123749:Hörmann, Karl  |d 60000  |d 62100  |e 60000PH130123749  |e 62100PH130123749  |k 0/60000/  |k 1/60000/62100/  |p 3 
998 |g 12385900X  |a Pfaar, Oliver  |m 12385900X:Pfaar, Oliver  |d 60000  |d 62100  |e 60000PP12385900X  |e 62100PP12385900X  |k 0/60000/  |k 1/60000/62100/  |p 1  |x j 
999 |a KXP-PPN1824360223  |e 4223252569 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"subtitle":"which outcome measures are useful in monitoring clinical trials?","title_sort":"Allergen-specific immunotherapy","title":"Allergen-specific immunotherapy"}],"person":[{"family":"Pfaar","given":"Oliver","display":"Pfaar, Oliver","role":"aut"},{"role":"aut","family":"Kleine-Tebbe","display":"Kleine-Tebbe, Jörg","given":"Jörg"},{"family":"Hörmann","display":"Hörmann, Karl","given":"Karl","role":"aut"},{"family":"Klimek","display":"Klimek, Ludger","given":"Ludger","role":"aut"}],"recId":"1824360223","name":{"displayForm":["O. Pfaar, J. Kleine-Tebbe, K. Hörmann, L. Klimek"]},"origin":[{"dateIssuedDisp":"28 April 2011","dateIssuedKey":"2011"}],"relHost":[{"note":["Gesehen am 18.01.11"],"id":{"issn":["1557-8607"],"zdb":["2222334-4"],"eki":["507904974"]},"part":{"pages":"289-309","year":"2011","text":"31(2011), 2, Seite 289-309","volume":"31","issue":"2","extent":"11"},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Immunology and allergy clinics of North America","title":"Immunology and allergy clinics of North America"}],"origin":[{"publisherPlace":"Amsterdam [u.a.]","dateIssuedKey":"1996","dateIssuedDisp":"1996-","publisher":"Elsevier"}],"pubHistory":["Nachgewiesen 16.1996 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"disp":"Allergen-specific immunotherapy which outcome measures are useful in monitoring clinical trials?Immunology and allergy clinics of North America","recId":"507904974"}],"note":["Gesehen am 02.12.2022"],"physDesc":[{"extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["1824360223"],"doi":["10.1016/j.iac.2011.02.004"]}} 
SRT |a PFAAROLIVEALLERGENSP2820